Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin

Arch Immunol Ther Exp (Warsz). 1994;42(4):269-74.

Abstract

We assessed the antiproliferative effect of tumor necrosis factor alpha (TNF-alpha) and lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, alone and in combination, on two murine tumor cell lines. Recombinant TNF-alpha inhibited proliferation of murine MmB16 melanoma cells in a concentration-dependent fashion but stimulated growth of murine L1210 leukemia cells at 0.1 ng/ml concentration. Lovastatin inhibited proliferation both of murine MmB16 melanoma cells and of murine L1210 leukemia cells in a concentration-dependent fashion. In combination with tumor necrosis factor alpha lovastatin inhibited synergistically growth of both cell lines as assessed by isobologram analysis. Our data show that lovastatin, a cholesterol synthesis inhibitor, introduced to the clinic to treat hypercholesterolemia, used either as a single or in combination with TNF-alpha inhibits growth of MmB16 melanoma and L1210 leukemia cells.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Division / drug effects
  • Drug Synergism
  • Growth Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lamins
  • Leukemia L1210 / pathology
  • Lovastatin / pharmacology*
  • Melanoma, Experimental / pathology
  • Mice
  • Nuclear Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins c-myc / antagonists & inhibitors
  • Recombinant Proteins / pharmacology
  • Tumor Cells, Cultured / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology*
  • ras Proteins / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • Growth Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lamins
  • Nuclear Proteins
  • Proto-Oncogene Proteins c-myc
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Lovastatin
  • ras Proteins